The use of oral nicotine pouches, particularly the popular brand Zyn, is surging among teenagers in a trend dubbed “zynning,” according to new research from the University of Southern California (USC). These small, tobacco-free pouches are placed between the gum and cheek to release nicotine, and their discreet, odorless nature is making them increasingly popular with youth.
Read moreA new campaign group, ‘20 Is Plenty‘, has launched in the UK to advocate for balanced and sensible regulation of nicotine pouches. The initiative is urging the government to introduce a 20mg maximum strength cap per pouch, describing it as a practical, evidence-based measure to protect public health without restricting adult access to these smoking and vaping alternatives.
Read moreIn the rapidly evolving landscape of nicotine products, a new category has surged into the mainstream, gaining considerable traction on social media and becoming particularly popular with young men in the U.S.: oral nicotine pouches (ONPs). Leading this boom is Zyn, a brand of small, teabag-like sachets that have become a financial boon for an industry grappling with declining cigarette sales. Tucked discreetly between the lip and gum, these pouches deliver a potent hit of nicotine without smoke, vapor, or spit. Marketed by the tobacco industry as a cornerstone of its “harm reduction” strategy, Zyn and its competitors are promoted as a safer way for adult smokers to consume nicotine. But as their use skyrockets among a demographic far broader than just transitioning smokers, critical questions about their safety, addictiveness, and long-term health effects are coming to the forefront. This guide delves into what we know – and, just as importantly, what we don’t – about this rising form of nicotine consumption.
Read moreFrance is set to ban nicotine pouches, referred to in a new decree as “oral use products containing nicotine,” in a significant move to combat the rising popularity of these products, especially among young people. The decree, published on September 6th, will prohibit the production, sale, transport, import, export, and consumption of these products in France, with the ban taking full effect six months after publication, on March 1, 2026.
Read moreThe U.S. Food and Drug Administration (FDA) is launching a new pilot program that will ease the research burden on nicotine pouch manufacturers, according to internal meeting transcripts reviewed by Reuters. This move is the first clear indication of a softer regulatory approach towards smoking alternatives under the Trump administration, potentially speeding up market access for major brands like Zyn, On!, and Velo.
Read moreThe U.S. Food and Drug Administration (FDA) is reportedly launching a pilot program to fast-track its review of nicotine pouches from four major tobacco firms: Philip Morris International (PMI), Altria, Reynolds American (part of British American Tobacco), and Turning Point Brands. According to meeting transcripts seen by Reuters, the program, which launched on Monday, aims to complete reviews of these products by December, a significant acceleration of a process that has previously taken years.
Read moreFor over a decade, U.S. public health bodies like the Centers for Disease Control (CDC) have often undermined non-pharmaceutical products that could aid in smoking cessation and tobacco harm reduction. This approach is a mistake. Smoking kills, and any tool that helps people reduce or eliminate their use of combustible tobacco—from patches and gums to vaping and nicotine pouches—should be accessible.
Read moreThe U.S. Food and Drug Administration (FDA) is strongly urging manufacturers of oral nicotine pouches to voluntarily adopt child-resistant packaging for their products. This call to action comes in response to a steady and concerning rise in reported cases of accidental nicotine pouch exposure among young children, some of which have resulted in nicotine poisoning.
Read moreTwo of the nation’s largest tobacco companies, Altria and Reynolds American, are moving forward with plans to launch new smokeless alternative products without waiting for formal marketing orders from the U.S. Food and Drug Administration (FDA). The companies argue that the FDA has failed to adhere to statutory deadlines for reviewing new product applications, creating a market imbalance where illegal, unauthorized vapes proliferate while their own regulated products are stuck in a lengthy review process.
Read moreThe U.S. Food and Drug Administration (FDA) has granted marketing authorization to 20 of Philip Morris International’s (PMI) ZYN brand nicotine pouch products, a landmark decision that solidifies the brand’s position as the leader in the rapidly growing smokeless nicotine market. The authorization, which covers various flavors including Wintergreen and the unflavored “Chill” in both 3 mg and 6 mg strengths, was met with a surge in PMI’s stock price as investors reacted to the regulatory green light.
Read moreAbout Ecigator
About Us
Business
- Authentication Check
- Press Release
- Store Location
- Stag Bar Vape